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Abstract
Parasitic sea lice represent a major sanitary threat to marine salmonid aquaculture, an industry accounting for 7% of world
fish production. Caligus rogercresseyi is the principal sea louse species infesting farmed salmon and trout in the southern
hemisphere. Most effective control of Caligus has been obtained with macrocyclic lactones (MLs) ivermectin and
emamectin. These drugs target glutamate-gated chloride channels (GluCl) and act as irreversible non-competitive agonists
causing neuronal inhibition, paralysis and death of the parasite. Here we report the cloning of a full-length CrGluCla
receptor from Caligus rogercresseyi. Expression in Xenopus oocytes and electrophysiological assays show that CrGluCla is
activated by glutamate and mediates chloride currents blocked by the ligand-gated anion channel inhibitor picrotoxin. Both
ivermectin and emamectin activate CrGluCla in the absence of glutamate. The effects are irreversible and occur with an EC50
value of around 200 nM, being cooperative (nH = 2) for ivermectin but not for emamectin. Using the three-dimensional
structure of a GluCla from Caenorabditis elegans, the only available for any eukaryotic ligand-gated anion channel, we have
constructed a homology model for CrGluCla. Docking and molecular dynamics calculations reveal the way in which
ivermectin and emamectin interact with CrGluCla. Both drugs intercalate between transmembrane domains M1 and M3 of
neighbouring subunits of a pentameric structure. The structure displays three H-bonds involved in this interaction, but
despite similarity in structure only of two these are conserved from the C. elegans crystal binding site. Our data strongly
suggest that CrGluCla is an important target for avermectins used in the treatment of sea louse infestation in farmed
salmonids and open the way for ascertaining a possible mechanism of increasing resistance to MLs in aquaculture industry.
Molecular modeling could help in the design of new, more efficient drugs whilst functional expression of the receptor
allows a first stage of testing of their efficacy.
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Introduction
Sea lice are marine ectoparasite copepods of the Caligidae
family (order Siphonostomatoida) that attach to host marine fish
and feed on their epidermal tissue, and blood. The Caligidae
family is constituted by hundreds of species belonging to the
Caligus and Lepeoptherius genera. Increasing interest in these
parasites has arisen owing to the ravages they produce on fish
aquaculture leading to morbidity and mortality with extremely
high economic impact in the industry. Lepeoptherius salmonis is
the most important caligid species affecting Northern hemisphere
salmon and trout aquaculture, and its biology, sensitivity to
chemotherapeutic drugs and distribution have been and presently
are very actively studied [1]. A different sea louse, Caligus
rogercresseyi is the most important parasite affecting Atlantic
salmon and rainbow trout sea water farming in Chile. This
Caligus was described as a separate species only in the year 2000
[2] and much remains to be known about its biology. As in the
Northern hemisphere, Caligus rogercresseyi infestation within the
nationally important Chilean aquaculture industry is associated
with increased costs and decreased productivity with high social
impact [Alvial et al. cited in 3].
Chemical treatment has been used in fish farms to combat sea
lice infestation with variable degree of success. Compounds used
include organophosphates, hydrogen peroxide, pyrethroids, chit-
ine synthesis inhibitors and avermectins [3]. Emamectin and
ivermectin are macrocyclic lactone avermectins that have been
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widely used to control parasitic infections in humans and animals.
Emamectin benzoate has been the treatment of choice for sea lice
treatment given its efficacy and ease of administration. The
compound, which is formulated as SLICE (Merck Animal Health),
is administered orally with fish feed and provides long-lasting
protection against all forms of attached sea lice.
Studies in nematodes have shown that avermectins interfere
with synaptic transmission through irreversible activation of
glutamate-gated chloride channel receptors leading to eventual
paralysis and death of the parasites [4]. Though highly successful
as antiparasitic drugs over extended periods of time, resistance to
avermectins has emerged and has become a major problem
worldwide [5].
Glutamate-gated chloride channels (GluCls) belong to the Cys-
loop receptor, or also known as pentameric ligand gated ion
channel, family which is widely present in nematodes and insects
[6–10]. Structurally they are pentamers and can assemble as
homopentamers or heteropentamers. Functionally characterized a
and b subunits (GluCl-a and GluCl-b subunits), also named GLC-1
and GLC-2, have been reported in the nematodes C. elegans
[11,12] and Hemonchus contortus [13]. The C. elegans GluCl
family now extends to six genes: glc-1 to glc-4, and avr-14 and avr-
15 [14]. In Drosophila melanogaster only one subunit is present,
DmGluCla, which is responsible for the insect sensitivity to
avermectin compounds [15]. The same seems to be the case in
most insects studied [14]. Recently our understanding of the
structural and functional properties of these receptors has made an
enormous progress thanks to development of the crystallographic
structure of Caenorabditis elegans GluCla subunit (CeGluCla) [16].
The structure revealed details of the agonist binding site in the
extracellular domain as well as the ivermectin site. The physiolog-
ical role of these receptors in invertebrates is to mediate and regulate
the inhibitory synapses and cellular excitability making them a very
important and effective pharmacological target for insecticides [14].
Emamectin has been used to combat infestation by Caligus
rogercresseyi in Chilean farmed salmon systems since 2000 [2], but
reports of growing resistance to the drug have emerged [17]. A
detailed knowledge of the molecular mechanisms of this resistance
is essential in devising strategies to circumvent it. We think that
characterizing the pharmacological target of emamectin benzoate
from C. rogercresseyi could help to understand the resistance
mechanisms and to design new drugs. Given that this molecular
entity is not known in this species, our aim in the present work was
to identify an emamectin sensitive chloride channel and charac-
terize its electrophysiological properties in oocytes of Xenopus
laevis and, taking advantage of the availability of a molecular
structure of member of the pentameric ligand gated ion channel




Caligus rogercresseyi specimens were obtained from three
different sources. The first were specimens obtained locally at
the Universidad Austral, Valdivia, Chile. The product (see below)
obtained from these specimens is hereafter referred to as CrGluCl-
Vald. The other sources were salmonid cages located in the
Darwin and Erra´zuriz Channels in Southern Chile, and their
products are referred to as CrGluCl-Dw and CrGluCl-Err,
respectively. All samples were collected in situ and immediately
stored in RNA-later protective solution (Ambion) at 220uC until
use. Pools of 6 to 10 adult specimens were pulverized under liquid
nitrogen and immediately mixed with Trizol reagent (Invitrogen)
to extract total RNA following the supplier instructions. The RNA
concentration was quantified based on absorbance at 260 nm and
its integrity evaluated by agarose gel electrophoresis.
Cloning of the glutamate gated chloride channel
Two degenerate oligonucleotides were designed based on an
amino acid region highly conserved in arthropod glutamate gated
chloride channels (GenBank accession number: NP_001171232,
NP_001071277, NP_001103244, NP_732447, ABI95855). The
forward (PCRdegFor(d64)) and reverse (PCRdegRev(d16)) corre-
sponds to MEYSVQLTFRE and KTNTGEYSC amino acid
sequences respectively. The reverse transcription reaction was
performed in 5 mg of total RNA primed with oligodT and random
primers using Superscrit II kit (Invitrogen). KOD Hot Start DNA
polymerase (Novagen) was used for PCR amplification and the
amplicon was subcloned in pGEM-T (Promega) vector and
analyzed by sequencing. The 59 cDNA was obtained by 59RACE
and inverse PCR based on the protocol published by Huang,
which combines the template-switching effect with inverse PCR
[18]. Briefly, the reverse transcription conditions using Superscrit
II were basically as supplier recommends except that the mix
contained T-S primer for template switching effect. One ml of
reverse transcription was used to synthesize the second strand with
T-S PCR and PCRdegRev(d16) primers and KOD Hot Start
DNA polymerase. The PCR product was purified by column
(Wizard, Promega) and quantified. 200 ng of the product were
phosphorylated with Polynucleotide kinase (New England Biolabs)
and then ligated with T4 DNA ligase (Fermentas). That ligated
product was used as template for inverse PCR (PCRi). A PCRi
number 1 was performed with PCRiFor1 and PCRiRev1 primers
and the product was used as template for PCRi number 2 using
PCRiFor2 and PCRiRev2 primers. The 39 cDNA end was
obtained using oligodT with an anchor sequence (cDNA Cloning
Primer) in the reverse transcription reaction. The second strand
was synthesized with KOD Hot Start DNA Polymerase using 1 ml
of transcription reverse product as template and PCRiFor1 and
PCR RACE 39 primers (first PCR). A second PCR reaction was
performed using as template the PCR product from the first
reaction with the PCRiFor2 and PCR RACE 39 primers. To
obtain the full length open reading frame (ORF) the cDNA was
amplified with the PCRfullFor and PCRfullRev primers. The
same cDNA was used to amplify 3 partial fragments by
Author Summary
Sea lice are the main parasites affecting farmed salmon
and trout in the world. Caligus rogercresseyi is the principal
sea louse species infesting farmed fish in the southern
hemisphere. Successful control of these parasites has been
achieved using macrocyclic lactones (MLs), but resistance
has emerged over time. In other invertebrates, MLs target
membrane receptors regulating synaptic transmission in
the parasite nervous system. Here we identify and study
the function of such a receptor from Caligus rogercresseyi,
and gain an idea about how two MLs, ivermectin and
emamectin, interact with the receptor to produce their
effects. Our molecular modeling of the protein in complex
with the drugs suggests a novel way in which ivermectin
and emamectin exert their effects on CrGluCl due to a lack
of conservation at interaction sites identified in the crystal
structure of the receptor from C. elegans. We believe that
the identification of a ML target in sea louse will aid the
study of drug-resistance mechanisms and could help in the
design of new, more efficient antiparasitic drugs.
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conventional PCR using the KOD Hot Start DNA polymerase
and the primers PCRfullFor and PCRiRev1, PCRmidFor and
PCRmidRev and PCR39For and PCR 39Rev. All the PCR
products were purified, cloned in the pGEM-T Easy vector
(Promega) and sequenced with T7 and SP6 primers. The full ORF
was excised from this vector with NotI enzyme and subcloned in
the pCR3.1 vector in the same site. The oligonucleotides used in
the cloning procedure are listed in Table S1.
Expression vector construction
To express the channels in Xenopus laevis oocytes, the ORF was
cut with BglII and XbaI from crGluCl/pCR3.1 and directionally
subcloned in the pTLB and a BamHI site was inserted
downstream to the stop codon.
cRNA preparation
The plasmids crGluCl/pTLB were linearized with BamHI
enzyme (Roche) and used as template for synthesis of capped
cRNA using mMessage Machine SP6 kit (Ambion, Austin, TX,
USA).
Voltage-clamp in Xenopus laevis oocytes
Defolliculated oocytes were injected with 5 ng, 10 ng and 20 ng
of each cRNA and kept at 16uC in modified Barth’s solution for 5
days. Two-electrode voltage clamp recording were performed at
room temperature using TURBO TEC-10CX (npi electronic
GmbH, Tamm, Germany) and PClamp 9 software (Axon
Instruments, USA), from 2 to 4 days after oocyte injection.
Oocytes were recorded in a chamber (Model RC-1Z, Warner
Instrumenst, USA) under continuous superfusion. Electrodes were
pulled to 0.5–2 MV and filled with 3 M KCl. The bath reference
was 3 M KCl in a 3% agar bridge connected to an Ag–AgCl
pellet. Currents were recorded in response to a ramp protocol
consisting in a holding potential period of 230 mV for 40 ms
followed by a voltage jump to 2100 mV for 20 ms. The ramp was
from 2100 mV to +60 mV with a 360 ms duration. The data
Figure 1. Alignment of CrGluCla amino acid sequence with other glutamate-gated chloride channel a subunits. PROMALS3D program
(http://prodata.swmed.edu/promals3d/) was used to generate an alignment with the following glutamate receptor GluCla proteins: L. salmonis (Ls)
GI:115361509, D. melanogaster (Dm) GI:1507685 and C. elegans (Ce) GI:559559. The predicted signal peptide of CrGluCla, identified using SignalP 4.1
programme, is shown in bold italic. M1–M4 are transmembrane domains; cysteines involved in C-loops are highlighted in yellow; in grey and in red
are residues involved in glutamate and ivermectin binding respectively. Arrows indicate amino acids variations between Caligus obtained from
different sources (see Figure 2). The position of the transmembrane domains and binding sites is based on the crystal structure of the C. elegans
GluCla [16].
doi:10.1371/journal.ppat.1004402.g001
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were filtered at 1 kHz, digitized using a digidata 1440A analogue-
to-digital converter and analyzed using Axon pClamp 9 software.
The solution bathing the oocytes during electrophysiological
recordings had the following composition (mM): 115 NaCl, 2
KCl, 1.8 CaCl2, 1 MgCl2, 10 HEPES pH 7.5 obtained with
NaOH. For the low [Cl2]o solution all NaCl was replaced with the
gluconate Na salt. Stock solutions of the drugs in DMSO were:
emamectin 10 mM, ivermectin 10 mM, picrotoxin 100 mM.
Different concentrations of the drugs were obtained by dilution
in bathing solution. The highest DMSO concentration used was
seen to have no effect on CrGluCl currents. Analysis of
concentration-dependence of glutamate or drug effects was done
by fitting a Hill model to the data using the non-linear regression
suite of Sigmaplot 12.
Molecular modelling of CrGluCla structure
In the absence of structural data for the GluCl receptor of
Caligus rogercresseyi (CrGluCla), we built a model to help our
understanding of experimental results. CrGluCla shares a 53%
sequence identity with CeGluCla whose high resolution X-ray
diffraction structure has been resolved [16] (comparison of
similarly truncated CrGluCla as crystallized CeGluCla). We used
these data (PDB ID 3RHW) as a reference structure to build a
homology model of CrGluCla using Modeller v 9.10 software
[19]. The molecular model was embedded into a 1306130 A˚
POPC lipid bilayer in a water box. The hydrated system was
neutralized with NaCl at a concentration of 150 mM. The system
was submitted to a molecular dynamics simulation under periodic
bordering conditions (13561356165 A˚3) and isobaric-isothermal
ensemble (NPT). The full system was relaxed through molecular
dynamics (MD) simulations using NAMD 2.9 software [20] for
1 ns and subsequently equilibrated for 20 ns.
Docking simulations
The homology model structure was used in docking simulations
to identify ivermectin and emamectin binding sites in CrGluCla.
The molecular docking procedure used Glide [21] software of the
Schro¨dinger suite. The drugs, that belong to the macrocyclic
lactone group, were designed using Maestro 2D sketcher [22], and
prepared with LigPrep [23]. The CrGluCla model was prepared
using the Protein Preparation Wizard [24] panel, assigning bond
order, adding missing hydrogen atoms, correcting metal ionization
states and creating disulphide bonds.
Grid size and position was defined from the position of
ivermectin observed in the CeGluCla-ivermectin complex crystal
structure. The box centre was defined as the midpoint of a line
joining the two most distant atoms of the ligand core. The size of
the grid was fixed at 22 A˚, considering a distance of 34634634 A˚
in the coordinate axis.
A flexible docking was done using the OPLS-AA force field with
standard precision (SP). This approach is appropriate for ligand
screening in model-derived structures. To internally generate
Figure 2. Variations in deduced CrGluCla primary structure. The rooted phylogenetic tree was done by using the UPGMA method after
aligning twelve representative clones with CLUSTALW software (http://www.genome.jp/tools/clustalw). The positions of amino acid changes (V27I,
D73G, R387K and L411Q), or deletions (isoleucine 20 (I or D), and alanine 376 plus serine 377 (AS or D)) are shown. The clone name is composed by
CrGluCla, source and Arabic number. Source: Valdivia (Vald), Darwin (Dw) and Erra´zuriz (Err). Arabic number is the number assigned during the
cloning process.
doi:10.1371/journal.ppat.1004402.g002
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Figure 3. Glutamate-activated picrotoxin-sensitive currents of CrGluCla RNA-injected Xenopus oocytes. A. Current traces obtained at
the indicated membrane potentials during bath application of glutamate at concentrations from 1 to 100 mM during the times shown in the boxes.
Current and time calibration bars shown apply also to recordings shown in panels B and D. B. Picrotoxin (PTX) at 100 mM reversibly abolishes
glutamate-evoked current. The trace illustrated was taken at 60 mV. Respective current voltage relations taken from voltage-ramps applied during
Sea Louse Glutamate- and Avermectin-Gated Chloride Channel
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conformations, the ligand was considered flexible during the
coupling process. A postdocking minimization allowed optimiza-
tion of bond lengths and angles, including torsion angles. Owing
the fact that this kind of docking code has not been adjusted to
transmembrane conditions some spatial restraints were applied to
guide the conformational sampling in the binding site. In order
to try and reproduce the H-bonding network observed in the
ivermectin binding in the crystallographic data [16], distance
restraints were applied between Thr305 (Ser321 in the crystal) and
ivermectin (and emamectin) O10 and between Leu263 and
ivermectin (and emamectin) O13.
Molecular dynamics
Three systems were considered: CrGluCla, and the CrGluCla-
ivermectin and CrGluCla-emamectin complexes. Each system was
embedded into a POPC lipid bilayer in a water box (dimensions:
13561356165 A˚3) and a NaCl concentration of 150 M. NAMD
software [20] was used to relax each system through molecular
dynamics (MD) simulations. MD was performed with the
CHARMM force field and the TIP3P water model [25]. The
temperature was kept at 300uK with the isobaric-isothermal
ensemble using Langevin dynamics with a damping coefficient of
1 ps21. By means of the Langevin Piston method the pressure was
fixed at 1 atm. The equations of motion were integrated
employing the Verlet r-RESPA algorithm [26] with a time step
of 2 fs. All systems were subjected to energy minimization using
periodic boundary conditions.
Pore radius calculations
After a brief stabilization of each system, HOLE algorithm [27]
was used to determine channel pore dimensions, by using the
coordinates of the ion channel. Pore dimensions obtained
considered the last 10 ns of trajectory (total time 100 ns).
Results
Cloning of the glutamate gated chloride channel
The GeneBank database was explored for the presence of
sequences for glutamate-gated chloride channels belonging species
phylogenetically close to Caligus rogercresseyi. The search
produced sequences for Lepeoptheirus salmonis, Drosophila
melanogaster, Nasonia vitripennis, Apis mellifera and Tribolium
castaneum, which were used to design degenerated primers to
attempt cloning a fragment of the receptor from C. rogercresseyi
total RNA. The PCR amplification with the degenerated primers
(Table S1) gave rise to a product of approximately 450 bp which
included the two extracellular domain Cys-loops characteristic of
these receptors. The predicted amino acid sequence of this
fragment showed a 90% identity with the sequence from L.
salmonis and 74% with that of D. melanogaster. Based on this
sequence we designed specific primers to amplify the cDNA ends
of the channel. In the 59 and 39 RACE experiments we obtained
PCR products of 700 bp (59) and 900 bp (39). The predicted
amino acid sequences were 79% (59) and 83% (39) identical to
those of a putative receptor from L. salmonis and 62% (59) and
55% (39) with that of D. melanogaster. In the 59 RACE sequence
we found an ATG with many upstream in frame stop codons. We
considered this ATG as the start codon.
After identifying the sequences of the cDNA ends, we designed
specific primers to amplify by PCR the full ORF cDNA. RT-
PCRs were carried out using RNA purified from C. rogercresseyi
from the three geographical sources mentioned above. The
amplification yielded products of approximately 1.4 kb (Figure
S1) with predicted amino acid sequence showing the general
features of the known glutamate gated chloride channels, such as
a putative signal peptide preceding the large extracellular
N-terminus, two Cys-loops, four transmembrane domains and a
shorter C-terminus. In Figure 1, we show a representative clone
aligned with the partial sequence available for a putative GluCla
from northern hemisphere sea louse Lepeophterius salmonis, and
the glutamate-gated chloride channel a-subunits of Drosophila
melanogaster and Caenorabditis elegans. The closest to the
CrGluCl sequence was that of DmGluCla, which showed a 60%
identity and 75% of similarity, with respective figures of 46% and
62% for the comparison with CeGluCla full-length subunit. A
more detailed analysis of 33 full-length clones showed some
differences in the predicted protein sequence. Predicted sizes
ranged from 461 to 464 amino acids and the differences were due
to either insertion of one isoleucine at positions 20 (I or D) and/or
deletion of alanine 376 together with serine 377 (AS or D) (see
Table S2). In addition, the analysis also revealed 16 amino acid
changes (Table S3). To determine if these were genuine differences
or whether they originate in PCR errors we amplified smaller,
overlapping fragments of the cDNA. Sequencing of the partial
clones confirmed the following amino acidic differences, V27I,
D73G, R387K and L411Q, plus the above mentioned insertion
and deletion. We conclude therefore that they probably represent
allelic variants of the protein. Combinations of the precedent
variants give rise to 12 different clones whose phylogenetic analysis
is shown in Figure 2.
Functional expression of C. rogercresseyi GluCla in
Xenopus laevis oocytes
To evaluate electrophysiologically the functional properties of
C. rogercresseyi GluCl we utilised clones CrGluCl-Vald13 and
CrGluCl-Vald2 for oocyte expression. CrGluCl-Vald13 was the
most abundantly represented of the obtained clones, and
CrGluCl-Vald2 contains the greatest number of amino acidic
differences compared to CrGluCl-Vald13. As shown in Figure 2
these clones are positioned in the most distant branches of the
phylogenetic tree of the allelic variants found. No functional
difference whatsoever could be detected between the clones. The
results shown below pertain to CrGluCl-Vald13, but to calculate
averages these values were pooled with those of CrGluCl-Vald2.
The receptor is referred to hereafter simply as CrGluCla.
Figure 3A shows current traces obtained using two-electrode
voltage-clamp of an oocyte previously injected with CrGluCla
RNA. Outward and inward currents were recorded respectively at
60 and 280 mV. Superfusion with increasing concentrations of
L-glutamate led to a graded increase in current at both voltages.
Figure 3B shows that the glutamate-dependent current could be
reversibly inhibited by 100 mM picrotoxin (PTX), a known open
this experiment are shown in panel C. In panels D and E, it is shown that most of the glutamate evoked outward current is dependent on the
presence of extracellular Cl2, all but 7.6 mM of which was replaced by gluconate during the time identified as Low [Cl2]o. The current-voltage
relations in E have been corrected by subtraction of the current remaining in 100 mM PTX. Panel F shows a graph summarizing results (means6SEM
from 7 experiments) of the concentration-response relationship of the glutamate-sensitive currents. The responses were normalised to the maximal
effect evoked by glutamate. The line is a Hill equation fitted simultaneously to both280 and 60 mV data sets giving values for EC50 of 6.8960.83 mM
and nH of 1.3360.18.
doi:10.1371/journal.ppat.1004402.g003
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Figure 4. Irreversible activation of CrGluCla by ivermectin. A. Current trace obtained at 60 mV during bath application of 50 mM glutamate
and then to ivermectin at concentrations going from 1 to 3000 nM during the times shown in the boxes. The effect of picrotoxin addition at 100 mM
is shown at the end of the trace. The trace in panel B shows that whilst ivermectin-induced current blockade by picrotoxin is reversible, the current
evoked by the ivermectin is persistent even after prolonged washing. As for the glutamate response, ivermectin-induced outward current was greatly
decreased upon decreasing [Cl2]o to 7.6 mM. In C and D current voltage relations taken from voltage-ramps applied during experiment in B are
shown. Those in D have been corrected by subtracting the current remaining in the presence of 100 mM PTX. E. Dose-response relationship of the
Sea Louse Glutamate- and Avermectin-Gated Chloride Channel
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ligand-gated chloride channel pore blocker [28,29]. Average
current at 60 mV increased from 0.4960.043 to 3.0960.23 mA
upon addition of 100 mM glutamate (mean6SEM, n = 18).
Addition of PTX decreased the current to 0.4860.17 mA
(n = 14). Current voltage relations taken during addition of
100 mM glutamate before, during and after application of PTX
are shown in 3C. The glutamate-dependent current was outwardly
rectifying and reversed sign at a depolarized potential compared
with the residual current after inhibition with picrotoxin, whose
effect was fully reversible. The average reversal potential of the
glutamate-induced current was 22062.2 mV (mean6SEM,
n = 6). Figure 3D shows that the current elicited by glutamate
was carried by Cl2, as extracellular replacement with an
impermeant anion sharply reduced outward current (Cl2 influx).
Current-voltage relations were also taken during glutamate
application under normal and low extracellular [Cl2]. Figure 3E
shows these current-voltage relations that have been corrected for
the current remaining in 100 mM PTX, a concentration affording
maximal effect of the toxin (Figure S2). The outwardly rectified
current was markedly reduced in low external Cl2 solution and
the reversal potential was shifted in a depolarised direction, as
expected for a current carried by Cl2. The change in reversal
potential DErev was 5964.2 n = 6 (mean6SEM, n = 6), which did
not differ significantly (P = 0.087, one-sample t-test) from the DErev
value of 69 mV predicted for perfect selectivity for Cl2 over
gluconate. Figure 3F shows dose dependence of the glutamate
effect measured at 280 and 60 mV. There was no difference
between these measurements and a simultaneous fit of a Hill
equation to the data gave an EC50 of 6.8960.83 mM and nH of
1.3360.18.
The avermectin family of lactones such as ivermectin are potent
and irreversible activators of some ionotropic invertebrate
receptors. We have tested the effect of ivermectin on the currents
elicited in Xenopus oocytes by expression of CrGluCla. Figure 4A
shows a recording of CrGluCla current at 60 mV where addition
of a supramaximal activating concentration of 50 mM glutamate
produced the expected large increase in outward current.
Increasing concentrations of ivermectin also elicited a graded
increase in outward current readily inhibited by addition of the
channel blocker PTX at 100 mM. Figure 4B shows that ivermec-
tin-dependent current was reversibly inhibited by PTX in addition
to being dependent on the presence of Cl2 in the bath. In six
separate experiments ivermectin at 3 mM increased current from
0.3960.04 to 2.2160.43 mA, whilst addition of PTX decreased
ivermectin-dependent current to 0.4060.08 mA (means6SEM).
The figure also illustrates the irreversibility of ivermectin effect that
remains unabated after removal of the drug. Current-voltage
relations taken for ivermectin-activated current before and after
PTX inhibition are displayed in Figure 4C. The current-voltage
relations in Figure 4D have been corrected for the current
remaining in 100 mM PTX, in high and low external Cl2
solution. The reversal potential shifted in a depolarised direction
upon Cl2 reduction. The average change in reversal potential
DErev was 6066.7 mV (mean6SEM, n = 4) not significantly
different from 69 mV (P = 0.322), consistent with high Cl2
selectivity. Emamectin is another member of the avermectin
family widely used to combat sea louse infestation in fish
aquaculture in its benzoate form. CrGluCla-mediated current
was also irreversibly activated by emamectin in a dose-dependent
manner (Figure 5A). At 3 mM emamectin, current measured at
60 mV in CrGluCla-expressing oocytes increased from 0.4960.06
to 1.4260.13 mA whilst PTX at 100 mM reduced the current to
0.4060.09 mA (n = 13). Current elicited by a saturating concen-
tration of emamectin was smaller than that elicited by glutamate.
Addition of glutamate after activation with emamectin only
modestly increased current (Figure S3). Figure 5B shows that the
currents stimulated by the avermectins in Xenopus oocytes
expressing CrGluCl were outwardly rectified. Reversal potential
was 22162.5 (n = 13) mV for emamectin-elicited current, close to
the chloride equilibrium potential of Xenopus oocytes [30].
Figures 4E and 5C show respectively the dose-response curves
for ivermectin and emamectin derived from a number of
experiments at 60 and 280 mV. There was no significant
difference between values at these two voltages, and when
analysed together they gave EC50 values for ivermectin and
emamectin of 181610 and 202621 nM, with corresponding nH
values of 2.160.26 and 1.160.11.
Molecular modelling of C. rogercresseyi GluCla
CrGluCla shares a high percentage of sequence identity with
CeGluCla whose X-ray structure has been recently solved [16].
We have used this structure to build a homology model for the
Caligus receptor to be subsequently used in docking of emamectin
and ivermectin followed by molecular dynamics simulations. A
view of the resulting modeled structure can be seen in Figure S4.
All main features of the reference structure such as secondary
structure and side chain conformation were retained in the
molecular model of CrGluCla, as expected from the high
conservation of sequence particularly in the transmembrane
domains.
In order to validate the molecular model and protocol to be
used we performed a docking assay with the CeGluCla crystal
structure (PDB code 3RHW) and ivermectin. The results
produced a position, orientation and interactions of ivermectin
with the receptor, with a RMSD of 1.1 A˚, very close to those
reported in the co-crystallized complex. Interactions included H-
bonds with Ser321 and Thr346 in transmembrane domains 2 and
3, and Leu279 of M1 in the adjacent subunit, at respective donor-
acceptor distances of 1.9, 1.9 y 2.3 A˚. Notice that the numbering
used refers to the full-length deduced amino acid sequence
(Figure 1) and differs from that used for the crystallized protein
that contains some deletions [16]. The CeGluCla-ivermectin
docking assay had a GlideScore energy of 28.4 kcal/mol and
RMSD of 1.1 A˚ with respect to the crystal structure.
Docking assays of ivermectin and emamectin employing the
CrGluCla model gave the Glide scores values reported in Table 1.
Both drugs were seen to be inserted in between subunits and three
H-bonds were observed between CrGluCla and ivermectin or
emamectin (Table 1). Fig. 6A and B show the positioning of
ivermectin and emamectin with respect to the receptor, which
occurs between M3 on one subunit and M1 on the neighbouring
subunit. Both drugs wedge deeply between M3 and M1, with an
-OH group in their cyclohexene ring making H-bond contact with
Thr305 of M2 (Figure 6C–F, see Figure S5 for drug structures and
identity of groups involved in H-bonding). Two other H-bonds were
observed: with the backbone carbonyl oxygen of Leu263 in M1 and
with Thr318 at the extracellular end of M3. Residues participating
in H-bonding in the CeGluCla-ivermectin crystalographic structure
Ivermectin-sensitive currents. Data are normalized (mean 6 SEM) to the maximal effect of ivermectin and originate in five separate experiments. The
line is a Hill equation fitted simultaneously to measurements taken at 280 and 60 mV giving a value for EC50 of 181610 nM, with corresponding nH
value of 2.160.26.
doi:10.1371/journal.ppat.1004402.g004
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Figure 5. Irreversible activation by emamectin of CrGluCla receptor expressed in Xenopus oocytes. A. Current trace obtained at 60 mV
during bath application of emamectin at concentrations going from 5 nM to 10 mM during the times shown in the boxes. The effect of picrotoxin
addition at 100 mM is also shown immediately after removal of emamectin. Wash out of picrotoxin in the absence of emamectin returns current to
the levels attained in the presence of high concentration of emamectin. B: Current-voltage relations taken from voltage-ramps applied during
experiment in A. Control denotes current prior to emamectin addition. C. Dose-response relationship of the emamectin-sensitive currents. Data are
normalized (mean 6 SEM) to the maximal effect of emamectin and originate in seven separate experiments. The line is a Hill equation fitted
simultaneously to measurements taken at 280 and 60 mV giving a value for EC50 of 202621 nM and nH 1.160.11.
doi:10.1371/journal.ppat.1004402.g005
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[16] were Leu279 in M1, Ser321 in M2 and Thr346 in M3. Of
these, only the first is strictly conserved in CrGluCla (Leu263), with
the further two positions occupied by a threonine (305) and an
isoleucine (330), as shown in Figure 7. H-bonding at Leu263 and
Thr305 of CrGluCla take place with the same positions of
ivermectin as corresponding H-bonds at Leu279 and Ser321 in
the CeGluCla structure. The Thr318 H-link of CrGluCla is not
present in the C. elegans structure, where the corresponding
position is taken by Ile334. This H-bond of CrGluCla occurs at the
extracellular end of M3 and involves a hydroxyl (ivermectin) or an
-NH-CH2 group (emamectin) in the disaccharide moieties of the
drugs (Figure S5). This necessitates a bending upwards in the
structures of the drugs to reach the position of Thr318 (Figs. 6C–F).
Molecular dynamics was used to evaluate the stability of the
interactions between the protein and the ligands. Three different
configurations were run: CrGluCla on its own, the CrGluCla-
ivermectin and CrGluCla-emamectin complexes. Figure 6A and B
show the positioning of the transmembrane domains and the fit of
the drugs after 140 ns MD. Insertion of the drugs into the protein
tended to separate helix M3 in one subunit from M1 in an adjacent
subunit. It also appears that the top aspect of helix M2 moves away
from the pore. These alterations are similar to those described for
the crystal structure [16] and in MD studies of CeGluCla and other
pentameric ligand-gated ion channels [31,32]. Minimal diameters
measured at the transmembrane portion of the pore at the end of
these runs were in the order CrGluCla-ivermectin.CrGluCla-
emamectin.CrGluCla (Figure 8A), and are consistent with an
open channel configuration for the drug-receptor complexes. Points
of narrowest pore diameter in the receptor without drugs occurred
at Leu299 and P288 (Figure 8). These correspond to hydrophobic
seal amino acids in CeGluCla that are conserved in CrGluCla A
third narrowing of the pore (T308 in C. elegans) is absent in the
Caligus receptor where it is replaced by Ala292. Also shown in
Figure 8 are structures of the pore of CrGluCla in the absence of
drugs at the beginning and the end of the MD simulation. There
was a continuous water column at time zero (Figure 8C), that is
interrupted by the advance of Leu299 towards the lumen of the pore
at the end of the simulation (Figure 8B). The narrowing at P288 did
not interrupt the water column.
Identification of the amino acids in the receptor involved in
drug interaction considered residues at a distance ,3.0 A˚ during
at least 50% of the molecular dynamics time (averaged times of the
five interacting drug molecules). According to these criteria 14
residues were involved in ivermectin (15 for emamectin) binding
(see Figure 7), including H-bonding Thr305, Thr318, and
Leu263, with the rest involved in van der Waals interactions. All
five drug molecules remained at their binding sites during the
140 ns MD runs.
Functional analysis of CrGluCl-T318A mutant
The preceding in silico analysis of ivermectin and emamectin
interaction with CrGluCl revealed several characteristics also
found in the crystal structure of CeGluCla bound to ivermectin
but also some differences. The most salient divergence emerged in
the H-bonds between the avermectins and the receptor. With only
two of the three residues involved in CeGluCl conserved in the
Caligus channel a third, not previously described H-bond acceptor
emerged in the form of T318 at the extracellular end of M3. To
obtain independent evidence that T318 is involved in the
interaction of the avermectins with CrGluCl we mutated this
residue to H-bonding-incompetent alanine. Figure 9 shows the
result of CrGluCla-T318A expression in Xenopus oocytes that
exhibited high spontaneous current with addition of glutamate
evoking small increases in current and ivermectin inducing partial,
irreversible current inhibition (Figure 9A). The current associated
to CrGluCla-T318A expression is carried by Cl2 ions. This is
confirmed by its decrease upon [Cl2]o decrease and its blockade
by PTX. Figure 9B shows average spontaneous currents in
CrGluCla-T318A-expressing oocytes, as well as the increase in
evoked by glutamate, and the current decrease observed upon
addition of ivermectin or emamectin. Current-voltage relations for
spontaneous CrGluCla-T318A activity and that remaining after
reduction of extracellular Cl2 concentration, after correction for
that remaining in the presence of 100 mM PTX, are shown in
Figure 9C. The reversal potential, and therefore the resting
potential of CrGluCla-T318A-expressing oocytes was
21861.9 mV (mean6SEM, n = 9). The effect of lowering
[Cl2]o was to shift the reversal potential by an average DErev of
6266.9 mV (mean6SEM, n = 3), not significantly different from
the 69 mV expected for perfect Cl2-selectivity (P = 0.481, one-
sample t-test). Average responses to increases in glutamate are
shown in Figure 9D and compared to the response of WT
CrGluCla. Maximal response was reached at lower glutamate
concentrations in the CrGluCla-T318A mutant channel.
The data described suggest that CrGluCl-T318A mutant
receptor is spontaneously open and is inhibited by emamectin
and ivermectin. To study the efficiency of these inhibitory actions
we decided to compare the effect of the avermectins in channels
having reached what appears to be full opening under the effect of
a maximally effective concentration of glutamate. Figure 10A and
B show that either emamectin or ivermectin diminished the
glutamate-dependent current in receptors activated through
addition of 50 mM glutamate in a concentration-dependent
manner, reaching a non-zero minimal current at saturating drug
(6669% and 5968% of the initial current for emamectin and
ivermectin respectively, n = 6 for both sets). Similar experiments
performed using the CrGluCla-T318A mutant are seen in
Figure 10C and D. Maximal effects of emamectin or ivermectin
decreased the current activated by glutamate by 6665 and 6064%
(means6SEM, n = 6 for both experimental sets) respectively. The
concentration dependence of the effects of avermectins differed
between WT and T318A mutant CrGluCla receptors as shown in
the plots of normalised average responses to emamectin and
ivermectin in Figure 10E and F. Fits of Hill decay functions to
individual experiments gave half maximal inhibitory concentrations
for emamectin of 78622 and 244631 nM in WT and T318A
Table 1. Energy and affinity values for the best pose of ivermectin and emamectin in docking assays with CrGluCla molecular
model.
Compound GlideScore (kcal/mol) H-bonds (n) H-bonding residues and bond length (A˚)
Ivermectin 27.9 3 L263 (3.0) T305 (2.6) T318 (3.3)
Emamectin 28.0 3 L263 (3.0) T305(2.7) T318 (3.1)
doi:10.1371/journal.ppat.1004402.t001
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CrGluCla receptors respectively (means6SEM, n = 6 for both sets
of experiments, t-test p = 0.007). Corresponding values for iver-
mectin inhibition were 3063.6 and 340691 nM (means6SEM,
n = 6 for both sets of experiments, t-test p = 0.001). Values for nH
were not significantly different from unity except for WT ivermectin
data that gave an nH value of 1.960.4.
Discussion
Parasitic nematodes, insects and crustaceans are pathogenic or
act as disease vectors to man and other vertebrates. The study of the
neurobiology of these invertebrates has been spurred by the search
of compounds that interfere with their physiological processes and
might therefore serve as chemotherapeutic agents for their control.
The glutamate-gated chloride channels GluCls are neuronal or
muscle receptors that have been described only in invertebrates.
This makes them a very interesting pharmacological target for
specific agents affecting parasites without interference with the
physiology of their vertebrate hosts. Macrocyclic lactones are drugs
that activate or modulate the activity of GluCls and have been
widely and successfully used as insecticides and antiparasitic agents
in human and veterinary medicine and in agriculture [14,33].
One example of a devastating parasitic problem within an
industrial context is the infestation of farmed salmonids with sea
lice [3]. MLs ivermectin and, more recently, emamectin have been
used successfully to fight these parasites both in the Northern
(Norway, Canada, Scotland) and the Southern hemisphere (Chile),
where the respective main species involved are Lepeophtherius
salmonis and Caligus rogercresseyi. In both regions, however, ML-
resistance has developed by underlying mechanisms that remain
essentially unknown [17,33–35]. Possible ways in which drug
resistance can arise include a change in the pharmacological target
causing the failure of the drug to bind or transduce its binding into
the molecular effect, changes in drug metabolism or active
removal the drug from the parasite, the host or both perhaps by
drug-induced differential gene expression [5,36].
By analogy with other species of nematodes and insects, it is
thought that MLs act on sea louse through irreversible binding to
c-aminobutyric acid and GluCl channels, causing paralysis leading
to death. Ivermectin resistance has been associated with mutations
in GluCl leading reduced ML-sensitivity in C. elegans and D.
Melanogaster [37–39]. This mechanism has not been explored in
sea lice as GluCl channels have not been identified molecularly in
these species.
An early attempt to obtain a cDNA for GluCl from L. salmonis
yielded a fragment lacking a start codon [40] which, not
surprisingly, failed to produce functional glutamate receptors
[41]. The GluCl cDNA isolated here is predicted to result in a
Figure 6. Interaction of emamectin and ivermectin with CrGluCla: results of molecular docking and molecular dynamics
experiments. A and B. The final conformation of the transmembrane domains (M1–M4) of CrGluCla for each subunit (S1–S5) after 140 ns MD runs
are shown schematically for the receptor after docking with ivermectin (A) or emamectin (B). Emamectin and ivermectin are shown as stick structures.
C–F. Higher magnification views of the drug positions in their binding sites. Dotted lines in E and F indicate H-bonds with the residues in stick
structures. The view in C and D is from above the channel having removed the extracellular domain. That in E and F is a side-view. Different colours of
the transmembrane domains indicate different subunits. Ivermectin and emamectin are displayed with their disaccharide moiety in yellow with the
rest of the molecule in orange.
doi:10.1371/journal.ppat.1004402.g006
Figure 7. Conservation of residues involved in drug binding in Caligus and C. elegans GluCla. Residues involved in hydrogen-bonding
(green) and van der Waals (grey) interactions of ivermectin or emamectin with CrGluCla (CrGluCla-IVM, CrGluCla-EMA, see text) are compared with
those identified in the CeGluCla-ivermectin complex (CeGluCla-IVM) [16]. Only those interactions existing during .70 ns of the 140 ns MD runs are
shown. Residues highlighted in red are those apparently involved in creating a hydrophobic seal in the channel pore in the absence of agonists [31].
doi:10.1371/journal.ppat.1004402.g007
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461–464 protein with a putative signal peptide preceding the large
extracellular N-terminus, two Cys-loops, four transmembrane
domains and a shorter C-terminus. Our sequencing data analysis
showed 12 different clones. All the differences were concentrated
in the amino end and in the loop located between transmembrane
domains 3 and 4, both highly variable regions in glutamate gated
chloride channels (see blue arrows in Figure 2). These variable
residues have not been reported as involved in glutamate or
ivermectin response in other glutamate and ivermectin gated
chloride channels so these differences were not predicted to cause
changes in the possible functional properties of expressed proteins.
Indeed clones 13 and 2 (see Figure 2), the most divergent
sequences encountered, gave indistinguishable activities when
assayed electrophysiologically after expression in Xenopus oocytes.
Closest homology of CrGluCla was with CeGluCla and
DmGluCla subunits [11,42]. Homology with the partial GluCl
sequence of Northern hemisphere sea louse Lepeophtherius
salmonis was also high [40]. Despite sequence homology there
are differences in the functional characteristics of CrGluCla and
those CeGluCla and DmGluCla. CrGluCla-expressing Xenopus
oocytes show glutamate-dependent ion currents which, unlike
those of DmClGlua [42], do not desensitize. No pretreatment was
needed to elicit CrGluCla-mediated currents as is the case for
those mediated by CeGluCla that does not show a glutamate
response unless previously activated by ivermectin [43]. CrGluCla
sensitivity to glutamate is similar to that of DmGluCla [42], with
EC50 values of 7 and 23 mM respectively, but with the Caligus
receptor showing little cooperativity (nH 1.3) compared with
DmGluCla (nH 2.0). Concerning the effect of ivermectin, both
CeGluCla and DmGluCla show activation with respective EC50
values of 140 and 40 nM [11,42] compared with the 180 nM
ivermectin EC50 of CrGluCla. The effect of ivermectin on
CrGluCla was cooperative, with a Hill coefficient of 2.1. This was
more reminiscent of that obtained with CeGluCla subunits than
with the Drosophila a subunit, which shows little cooperativity.
Judging by the potency of the ivermectin effect, the receptor of
Caligus studied here falls within a group of Cys-loop anionic
receptors showing the highest affinity ivermectin binding sites [44].
Emamectin benzoate is thought to act in a similar way to
ivermectin and has become the chemotherapeutic drug of choice
in the treatment of sea louse infestation in the salmon industry
[33]. We are not aware, however, of any study of the effect of
emamectin on GluCl receptors. Here we show that emamectin
activates CrGluCla irreversibly with an EC50 of 202 nM and nH
of 1.1. The similar potencies for emamectin and ivermectin action
together with similarities in structure suggest also a similar mode of
action.
Interestingly, the structure of CeGluCla has recently been
obtained by X-ray crystallography [16] giving insights into the
glutamate and ivermectin binding sites as well as on the site of
action of pore inhibitor picrotoxin. The molecular structure of
CeGluCla-ivermectin-glutamate reveals nine residues involved in
glutamate binding and eight of these are identical in CrGluCla
(Figure 1).
The crystal structure of CeGluCla also shows three residues H-
bonding with ivermectin, only two of which are conserved in
CrGluCla and are seen to H-bond with ivermectin and
emamectin in docking assays. A third H-bonding residue in
CeGluCla, namely Thr346 that H-links with the spiroketal moiety
of ivermectin, is not conserved in CrGluCla. Instead, Thr318 in a
region of M3 closer to the extracellular aspect of the channel in
CrGluCla H-bonds with the disaccharide end of ivermectin or
emamectin. Lack of conservation of CeGluCla Thr346 is also seen
in a GluCla receptor from the parasitic nematode Haemonchus
contortus [45] where the corresponding position is occupied by an
alanine. Interestingly this receptor shares with CrGluCla the
equivalent of Thr318 and responds to ivermectin in similar fashion
as the Caligus receptor [46]. The H-bonding between T318 of
Figure 8. A. Channel pore radius along the z-axis in the receptor alone (black) and in the CrGluCla-emamectin (green) and
CrGluCla-ivermectin (red) systems. A length, mainly intramembrane, of the pore is shown. The discontinuous lines show the pore segment lined
by M2 a-helices. Values have been taken at the end of MD trajectories. B and C. Lateral views of the pore at time zero (C) and at the end (B) of the MD
trajectory for CrGluCla in absence of drugs. Only four M2 helices are shown with the fifth removed for clarity. Residues P288, A292 and L299 are
shown in licorice. Water occupancy is shown as licorice and surface.
doi:10.1371/journal.ppat.1004402.g008
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Figure 9. CrGluCl-T318A expression in Xenopus oocytes. A. Current trace obtained in a CrGluCla-T318A-expressing oocyte that exhibited high
spontaneous current at the indicated membrane potential. Bath application of glutamate at concentrations from 1 to 100 mM took place during the
times shown in the boxes. This was followed by exposure to ivermectin, decrease of bath [Cl2] to 7.6 mM and addition of 100 mM PTX. B. Average
with SEM of spontaneous currents in CrGluCla-T318A-expressing oocytes (n = 7), and increase in current evoked by 100 mM glutamate (n = 7), and the
current decrease upon addition of ivermectin (n = 4) or emamectin (n = 5). C. Current voltage relations of spontaneous current exhibited in a
CrGluCla-T318A-injected oocyte in normal bath solution and after all but 7.6 mM extracellular Cl2 was replaced by gluconate. The current-voltage
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CrGluCla and the disaccharide moiety of ivermectin and
emamectin is novel and requires a bending upwards of the
disaccharide moieties of the drug molecules that departs markedly
from the topology of ivermectin seen in the crystal structure of
CeGluCla. Mutation T318A led to receptors that were sponta-
neously open, were only slightly enhanced by glutamate and
partially inhibited by emamectin or ivermectin. As we noticed in
the WT receptor, glutamate and the MLs activate macroscopic
currents of different amplitude, with the ML-activated currents
significantly smaller than those activated by glutamate. Similarly,
lower currents were obtained in the presence of MLs than with
glutamate using the CrGluCla-T318A mutant. The potency of
drug inhibition of open channels maximally activated by
glutamate showed an increased affinity of the avermectins for
their binding site in this configuration, perhaps suggesting that
splaying of the M1–M3 helices facilitating drug access. Compar-
ison of the EC50 values for ivermectin or emamectin inhibition of
WT receptors fully activated by glutamate and those activated by
mutation T318A shows that drug affinity was decreased by
replacement with the H-bonding-incompetent Ala.
We have not yet a testable hypothesis of a possible mechanism
for the T318A mutation-induced activation. We speculate that
breaking a putative intramolecular H-bond in which T318 plays
an acceptor role, either by the mutation or by action of the ML
drugs, could lead to opening of CrGluCla receptor. Interestingly a
disease-causing mutation at an equivalent site (V280M) in a
relations have been corrected by subtraction of the current remaining in 100 mM PTX. D. Concentration-response relationship of the glutamate-
sensitive CrGluCla-T318A currents (means6SEM from 7 experiments) normalised to the maximal effect evoked by glutamate. The response of WT
CrGluCla is shown for comparison.
doi:10.1371/journal.ppat.1004402.g009
Figure 10. Effect of ivermectin or emamectin upon CrGluCla-T318A-dependent currents. A and B. Effect of increasing concentrations of
emamectin and ivermectin on WT CrGluCla-dependent currents. The currents were first activated by addition of 50 mM glutamate and during
continuous exposure to glutamate increasing concentrations of emamemctin or ivermectin were added. Reduction of [Cl2] to 7.6 mM or addition of
100 mM PTX are also indicated. C and D. Similar experiments performed using the CrGluCla-T318A mutant. E and F. Concentration dependence of
the effects of avermectins on WT and T318A mutant CrGluCla receptors. Normalised average responses to emamectin and ivermectin are shown
(means6SEM, n = 6 for all experiments shown). Fits of Hill decay functions to the average values are shown by the solid lines.
doi:10.1371/journal.ppat.1004402.g010
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glycine receptor leads to spontaneously active channels [47]. It is
postulated that V280 might interact with residues in M1 to
stabilize the closed state of the channel. Our results, although not
entirely understood, point to the importance of T318 in the
interaction of emamectin and ivermectin with the Caligus
receptor. Perhaps future molecular simulations of the T318A
receptor could clarify the role of this residue that appears to play
an important part in the channel open-closed equilibrium.
Avermectin resistance through mutation in glutamate receptors
has been described. A naturally occurring mutation (G323D) at
M3 in a Tetranychus urticae GluCl (corresponding to Gly326 in
CrGluCla) markedly increases abamectin LD50 [48]. Human
GlyRa1 receptor has an alanine at the equivalent position (288)
and shows low sensitivity to ivermectin, which becomes 50-fold
higher in A288G-HsGlyRa1. The reciprocal mutation in
HcGlua3B, G329A, converts this normally high ivermectin-
sensitive receptor into a relatively resistant one [39]. This glycine
residue, conserved in GluCla channels, lies at the M3 domain
facing the drug binding cavity and it is conceivable that its
mutation alters M3 flexibility and the interaction of avermectins
with the receptor. This residue dubbed, M3-Gly, appears essential
for high ivermectin affinity and is highly conserved in GluCl
receptors [44].Mutation P299S, corresponding to P313 in
CrGluCla, also markedly decreases the ability of ivermectin to
activate DmGluCla [38]. The proline residue is located at the
M2–M3 loop that is thought to be stabilised by ivermectin in a
conformation favouring the open state [16]. Its mutation might
interfere with channel opening by avermectins without a direct
interaction with the drugs.
Van der Waals interactions were identified with twelve residues
of CeGluCla, with nine of those identical or similar in the Caligus
receptor (see Figure 7). Although not studied here in detail it
appears that the mechanism whereby ivermectin, and emamectin,
maintains CeGluCla open is by intercalating between subunits
leading to the separation of helices M1 and M3 of neighbouring
subunits [16]. As pointed out by Hibbs and Gouaux [16], the site
defined by the binding of avermectins in GluCla receptors appears
equivalent to that targeted in other pentameric ligand-gated ion
channels by modulators such as alcohol and anesthetics [49].
Another structural characteristic of receptors defined has having
high ivermectin sensitivity has been proposed to be the possibility
of making numerous H-bonding interactions in the vicinity of
S321 that was identified as H-binding in the crystal structure of the
C. elegans channel [16]. These possible H-bond partners are M2
T318, S321 and N325, and Q320 and Q280 of M2, and M1 in the
neighbouring subunit of the C. elegans receptor [44]. Their
corresponding residues in the Caligus channel are S302, T305
(identified as H-bond partner in our calculations), N309/Q304/
T264, thus conserving the capability for H-binding in this receptor
and possibly contributing to explain its affinity for ivermectin and
emamectin.
Our docking and MD calculations suggest that despite using the
same general binding pocket, ivermectin and emamectin are seen
at the Caligus receptor in a different conformation than that
revealed by the crystal of the C. elegans receptor-ivermectin
complex and form a different three-dimensional network of H-
bonds [16]. This observation, in addition to requiring more work
for its confirmation and better understanding, identifies a different
type of drug binding site in CrGluCla that could admit new types
of activity-modifying molecules.
We have presented here the first report of a full-length
ionotropic glutamate-gated GluCla from the salmon parasite
Caligus rogercresseyi. Our functional expression data strongly
suggest that CrGluCla is an important target for avermectins used
in the treatment parasitic infestation in salmon and trout and
opens the way for ascertaining a possible mechanism of increasing
resistance problems dogging aquaculture industry worldwide.
Molecular modeling and docking assays as we demonstrate here
could help in the design of new, more efficient drugs with
functional expression of the receptor allowing a first stage of testing
of their efficacy.
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Figure S1 Lanes are: 1: RT (+), 2: RT (2), 3: 1 kb ladder, and 4:
water control.
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Figure S2 Effect of picrotoxin (PTX) on CrGluCla-mediated
currents. A. Current measured at 60 mV in an oocyte expressing
the Caligus receptor. Additions to the bathing medium are shown
in the boxes above. B. Concentration dependence of PTX. The
points correspond to data from four separate experiments. The
EC50 of 3.2 mM is the mean of hyperbolic fits to the individual
data.
(PDF)
Figure S3 Comparison of the effects of saturation concentrations
of glutamate and emamectin on CrGluCla-mediated current
measured after expression in Xenopus oocytes. Data are means 6
SEM of number of experiments given in brackets.
(PDF)
Figure S4 Homology model of Caligus rogercresseyi glutamate
receptor CrGluCla. A: Vista lateral view. B. Upper view from the
extracellular side. The protein is shown in Newcartoon drawing
method. Transmembrane a-helices (M1–M4) are in blue, extra-
celluar b-sheets are shown in red, and coils in yellow.
(PDF)
Figure S5 Chemical structures of ivermectin and emamectin.
Sites involved in H-bond interactions with CrGlua as suggested by
the docking assays are indicated. M2 and M3 belong to one
subunit whilst M1 is in the neighbouring subunit. Images are from
the PubChem (http://pubchem.ncbi.nlm.nih.gov/) database.
(PDF)
Table S1 Primers used in PCR reactions at various stages of the
cloning of C. rogercresseyi GluCla receptor.
(PDF)
Table S2 Summary of amino acid differences in full length
clones. The upper row shows the two possible options of amino
acid or deletions with their respective positions. The bottom row
shows the number of times they were found. Highlighted in grey
are shown the groups that were selected as different branches to
build the phylogenetic tree of Figure 2 in the main text.
(PDF)
Table S3 Summary of amino acid differences in partial clones.
The differences, positions and number of times they occurred in
the study are shown as for Table S2. 31, 29 and 34 clones were
analyzed respectively for 59, middle and 39 fragments.
(PDF)
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